[Federal Register: August 6, 1999 (Volume 64, Number 151)] [Notices] [Page 42951] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr06au99-69] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Amoxicillin Injection for Sheep; Availability of Data AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of effectiveness, target animal safety, and human food safety data that may be used in support of a new animal drug application (NADA) or supplemental NADA for veterinary prescription use of amoxicillin injection for treatment of bacterial pneumonia in sheep. The data, contained in Public Master File (PMF) 5433, were compiled under National Research Support Project-7 (NRSP-7), a national agricultural research program for obtaining clearances for use of new drugs in minor animal species and for special uses. ADDRESSES: Submit NADA's or supplemental NADA's to the Document Control Unit (HFV-199), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. FOR FURTHER INFORMATION CONTACT: Naba K. Das, Center for Veterinary Medicine (HFV-133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7569. SUPPLEMENTARY INFORMATION: Amoxicillin injection, used for the treatment of sheep for bacterial pneumonia due to Pasteurella spp. and Haemophilis spp., is a new animal drug under section 201(v) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(v)). As a new animal drug, amoxicillin is subject to section 512 of the act (21 U.S.C. 360b), requiring that its uses in sheep be the subject of an approved NADA or supplemental NADA. Sheep are a minor species under Sec. 514.1(d)(1)(ii) (21 CFR 514.1(d)(1)(ii)). The NRSP-7 Project, Western Region, University of California, Davis, CA 95616, has provided target animal safety, effectiveness, and human food safety data for veterinary prescription use of amoxicillin injection in sheep for treatment of bacterial pneumonia due to Pasteurella spp. and Haemophilis spp. NRSP-7 did not provide information concerning potential environmental impacts of the manufacturing process. Such information is required upon submission of an application relying on this file to support approval. Data and information on safety and effectiveness are contained in PMF 5433. Sponsors of NADA's or supplemental NADA's may, without further authorization, reference the PMF to support approval of an application filed under Sec. 514.1(d). An NADA or supplemental NADA must include, in addition to reference to the PMF, animal drug labeling and other information needed for approval, such as data supporting extrapolation from a major species in which the drug is currently approved or authorized reference to such data, data concerning manufacturing methods, facilities, and controls, and information addressing potential environmental impacts of the manufacturing process. Persons desiring more information concerning the PMF or requirements for approval of an NADA or supplement may contact Naba K. Das (address above). In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information provided in this PMF to support approval of an application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Dated: June 29, 1999. George A. Mitchell, Acting Deputy Director, Center for Veterinary Medicine. [FR Doc. 99-20255 Filed 8-5-99; 8:45 am] BILLING CODE 4160-01-F